• Je něco špatně v tomto záznamu ?

Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease

F. Krackhardt, M. Waliszewski, V. Kočka, P. Toušek, B. Janek, M. Hudec, F. Lozano, KG. Roman, BG. Del Blanco, J. Mauri, TM. Heang, TH. Ahn, MH. Jeong, D. Herberger, V. Tomulic, G. Levy, L. Sebagh, J. Rischner, M. Pansieri,

. 2020 ; 34 (3) : 335-344. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024975
E-zdroje Online Plný text

NLK ProQuest Central od 1999-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1999-03-01 do Před 1 rokem

Odkazy

PubMed 32212061
DOI 10.1007/s10557-020-06963-5
Knihovny.cz E-zdroje

OBJECTIVES: The objective of this post hoc analysis was to analyze real-world dual antiplatelet therapy (DAPT) regimens following polymer-free sirolimus-eluting stent (PF-SES) implantations in an unselected patient population. METHODS: Patient-level data from two all-comers observational studies (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled and analyzed in terms of their primary endpoint. During the data verification process, we observed substantial deviations from DAPT guideline recommendations. To illuminate this gap between clinical practice and guideline recommendations, we conducted a post hoc analysis of DAPT regimens and clinical event rates for which we defined the net adverse event rate (NACE) consisting of target lesion revascularization (TLR, primary endpoint of all-comers observational studies) all-cause death, myocardial infarction (MI), stent thrombosis (ST), and bleeding events. A logistic regression was utilized to determine predictors why ticagrelor was used in stable coronary artery disease (CAD) patients instead of the guideline-recommended clopidogrel. RESULTS: For stable CAD, the composite endpoint of clinical, bleeding, and stent thrombosis, i.e., NACE, between the clopidogrel and ticagrelor treatment groups was not different (5.4% vs. 5.1%, p = 0.745). Likewise, in the acute coronary syndrome (ACS) cohort, the NACE rates were not different between both DAPT strategies (9.2% vs. 9.3%, p = 0.927). There were also no differences in the accumulated rates for TLR, myocardial infarction ([MI], mortality, bleeding events, and stent thrombosis in elective and ACS patients. The main predictors for ticagrelor use in stable CAD patients were age < 65 years, smaller vessels, treatment of ostial and calcified lesions, and in-stent restenosis. CONCLUSION: Within the framework of a post hoc analysis based on a real-world, large cohort study, there were no differences in the combined endpoint of major adverse cardiac events (MACE), bleeding and thrombotic events for clopidogrel and ticagrelor in stable CAD or ACS patients. Despite the recommendation for clopidogrel by the European Society of Cardiology (ESC), real-world ticagrelor use was observed in subgroups of stable CAD patients that ought to be explored in future trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024975
003      
CZ-PrNML
005      
20201222154956.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10557-020-06963-5 $2 doi
035    __
$a (PubMed)32212061
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Krackhardt, Florian $u Department of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow, Augustenburger Platz 1, D-13353, Berlin, Germany. Florian.Krackhardt@charite.de.
245    10
$a Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease / $c F. Krackhardt, M. Waliszewski, V. Kočka, P. Toušek, B. Janek, M. Hudec, F. Lozano, KG. Roman, BG. Del Blanco, J. Mauri, TM. Heang, TH. Ahn, MH. Jeong, D. Herberger, V. Tomulic, G. Levy, L. Sebagh, J. Rischner, M. Pansieri,
520    9_
$a OBJECTIVES: The objective of this post hoc analysis was to analyze real-world dual antiplatelet therapy (DAPT) regimens following polymer-free sirolimus-eluting stent (PF-SES) implantations in an unselected patient population. METHODS: Patient-level data from two all-comers observational studies (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled and analyzed in terms of their primary endpoint. During the data verification process, we observed substantial deviations from DAPT guideline recommendations. To illuminate this gap between clinical practice and guideline recommendations, we conducted a post hoc analysis of DAPT regimens and clinical event rates for which we defined the net adverse event rate (NACE) consisting of target lesion revascularization (TLR, primary endpoint of all-comers observational studies) all-cause death, myocardial infarction (MI), stent thrombosis (ST), and bleeding events. A logistic regression was utilized to determine predictors why ticagrelor was used in stable coronary artery disease (CAD) patients instead of the guideline-recommended clopidogrel. RESULTS: For stable CAD, the composite endpoint of clinical, bleeding, and stent thrombosis, i.e., NACE, between the clopidogrel and ticagrelor treatment groups was not different (5.4% vs. 5.1%, p = 0.745). Likewise, in the acute coronary syndrome (ACS) cohort, the NACE rates were not different between both DAPT strategies (9.2% vs. 9.3%, p = 0.927). There were also no differences in the accumulated rates for TLR, myocardial infarction ([MI], mortality, bleeding events, and stent thrombosis in elective and ACS patients. The main predictors for ticagrelor use in stable CAD patients were age < 65 years, smaller vessels, treatment of ostial and calcified lesions, and in-stent restenosis. CONCLUSION: Within the framework of a post hoc analysis based on a real-world, large cohort study, there were no differences in the combined endpoint of major adverse cardiac events (MACE), bleeding and thrombotic events for clopidogrel and ticagrelor in stable CAD or ACS patients. Despite the recommendation for clopidogrel by the European Society of Cardiology (ESC), real-world ticagrelor use was observed in subgroups of stable CAD patients that ought to be explored in future trials.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kardiovaskulární látky $x aplikace a dávkování $x škodlivé účinky $7 D002317
650    _2
$a nemoci koronárních tepen $x diagnostické zobrazování $x mortalita $x terapie $7 D003324
650    _2
$a koronární trombóza $x etiologie $x prevence a kontrola $7 D003328
650    12
$a stenty uvolňující léky $7 D054855
650    12
$a duální protidestičková léčba $x škodlivé účinky $x mortalita $7 D000080903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dodržování směrnic $7 D019983
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a pozorovací studie jako téma $7 D064887
650    _2
$a koronární angioplastika $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D062645
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $7 D010975
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a lékařská praxe - způsoby provádění $7 D010818
650    _2
$a protézy - design $7 D011474
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sirolimus $x aplikace a dávkování $x škodlivé účinky $7 D020123
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Waliszewski, Matthias $u Department of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow, Augustenburger Platz 1, D-13353, Berlin, Germany. Medical Scientific Affairs, B.Braun Melsungen AG, Berlin, Germany.
700    1_
$a Kočka, Viktor $u University Hospital Královské Vinohrady, Prague, Czech Republic.
700    1_
$a Toušek, Petr $u University Hospital Královské Vinohrady, Prague, Czech Republic.
700    1_
$a Janek, Bronislav $u IKEM, Prague, Czech Republic.
700    1_
$a Hudec, Martin $u SÚSCCH, a.s. Banská Bystrica, Slovak Republic.
700    1_
$a Lozano, Fernando $u Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
700    1_
$a Roman, Koldobika Garcia-San $u Hospital Universitario de Cruces, Bilbao, Spain.
700    1_
$a Del Blanco, Bruno Garcia $u Hospital Universitari Vall d'Hebron Barcelona, Barcelona, Spain.
700    1_
$a Mauri, Josepa $u Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
700    1_
$a Heang, Tay Mok $u Pantai Ayer Keroh Hospital, Malacca, MLK, Malaysia.
700    1_
$a Ahn, Tae Hoon $u Gachon University Gil Medical Center, Incheon, South Korea.
700    1_
$a Jeong, Myung Ho $u Chonnam National University, Gwangju, South Korea.
700    1_
$a Herberger, Denny $u Medical Scientific Affairs, B.Braun Melsungen AG, Berlin, Germany.
700    1_
$a Tomulic, Vjekoslav $u Clinical Hospital Center Rijeka, Rijeka, Croatia.
700    1_
$a Levy, Gilles $u Clinique du Millénaire, Montpellier, France.
700    1_
$a Sebagh, Laurent $u Clinique Turin Paris, Paris, France.
700    1_
$a Rischner, Jérôme $u Hôpital Albert Schweitzer Colmar, Colmar, France.
700    1_
$a Pansieri, Michel $u Centre Hospitalier d'Avignon, Avignon, France.
773    0_
$w MED00001057 $t Cardiovascular drugs and therapy $x 1573-7241 $g Roč. 34, č. 3 (2020), s. 335-344
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32212061 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222154952 $b ABA008
999    __
$a ok $b bmc $g 1599120 $s 1115661
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 3 $d 335-344 $e - $i 1573-7241 $m Cardiovascular drugs and therapy $n Cardiovasc Drugs Ther $x MED00001057
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace